Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there's positive growth in product sales and improved operating losses, the regulatory setbacks and lack of clear guidance on gross margins are concerning. The Q&A section reveals management's confidence in overcoming regulatory hurdles, but the lack of specificity and delays may worry investors. The stable gross margins and improved financial metrics are offset by increased operating expenses and regulatory uncertainties, resulting in a neutral sentiment. The absence of market cap information limits the prediction's precision.
Key Financial Performance
Product Sales $9.6 million, representing a 9% year-over-year increase and up 4% on a constant currency basis. Growth attributed to the reorganization and strategic realignment of the German commercial team, which grew 22% year-over-year and sequentially in the quarter. Other direct territories also showed strength, and distributor sales were among the best ever, second only to the record second quarter last year.
Gross Margin 70.9%, consistent with Q1 and full year 2024 margins but lower than 73.5% in Q2 of last year. The decrease was primarily due to inventory write-offs in the period.
Operating Expenses $10.4 million, approximately 3% higher than the prior year. Increase due to unique costs such as rebuilding the accounting team, regulatory legal consulting expenses related to DrugSorb ATR appeals, and costs associated with the German commercial restructuring.
Net Income $1.9 million or $0.03 per basic and diluted share, compared to a net loss of $4.3 million or $0.08 per basic and diluted share in the prior year. The improvement was influenced by foreign currency changes and other adjustments.
Adjusted Net Loss $3.7 million or $0.06 per basic and $0.05 per diluted share, compared to $2.8 million or $0.05 per basic and diluted share in the prior year. The increase in loss was due to higher operating expenses.
Adjusted EBITDA Loss $2.6 million, compared to $2.2 million in the prior year. The increase was due to higher operating expenses.
Cash, Cash Equivalents, and Restricted Cash $11.7 million as of June 30, compared to $13.1 million at the end of the first quarter. The decrease was due to a net cash burn of approximately $3.1 million, inclusive of unique items in the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CytoSorb: Flagship product used in intensive care and cardiac surgery for conditions like sepsis, septic shock, and liver failure. Approved in the EU and used in over 70 countries with nearly 300,000 devices utilized. Generated $35.6 million in core product sales last year.
DrugSorb ATR: Investigational FDA breakthrough device aimed at reducing perioperative bleeding in cardiac surgery patients on blood thinners. Potential market opportunity of over $300 million, with expansion to $1 billion as Brilinta becomes generic. Regulatory decisions from FDA and Health Canada expected by end of 2025.
Geographic Expansion: CytoSorb is used in over 70 countries worldwide. German market reorganization led to 22% year-over-year growth in Q2 2025. Distributor sales were among the best ever, second only to Q2 2024.
Operational Efficiencies: Gross margin steady at 71%. Operating expenses slightly higher due to unique charges, but company remains committed to reducing costs and driving efficiencies to achieve near breakeven by end of 2025.
Strategic Realignment: Proactive reorganization of German commercial team to improve execution and sales growth. Focus on driving core business to near breakeven and preparing for North American launch of DrugSorb ATR.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The company is facing regulatory hurdles with the FDA and Health Canada for its DrugSorb ATR device. The FDA issued a denial letter for the de novo application, and Health Canada issued a notice of refusal. Both are undergoing appeals processes, creating uncertainty around approval timelines and potential market entry.
Financial Pressures: Operating expenses increased due to unique charges, including regulatory legal consulting expenses, German commercial restructuring costs, and commercialization planning for DrugSorb ATR. The company is also experiencing a net cash burn, which could strain resources if regulatory approvals are delayed.
Market Dependency: The company’s largest market, Germany, has required a reorganization of its commercial team to reignite growth. This dependency on a single market for a significant portion of revenue poses a risk if the reorganization does not yield expected results.
Product-Specific Risks: DrugSorb ATR, a key growth driver, is still under regulatory review. Delays or denials in approval could significantly impact the company’s financial and strategic plans, as the product represents a major revenue opportunity.
Operational Efficiency: Efforts to achieve near-term breakeven and long-term financial independence are contingent on reducing costs and improving operational efficiencies. Failure to meet these goals could impact the company’s ability to sustain operations and fund new initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects stronger execution, improved performance, and more robust sales growth in its overall business this year and beyond, driven by the reorganization of its German commercial team and other direct territories.
Gross Margin: Gross margin performance is expected to remain solid, with production volumes increasing in the second half of the year to support core business growth and prepare for the anticipated launch of DrugSorb ATR in the U.S. and Canada.
DrugSorb ATR Regulatory Decisions: Final regulatory decisions from the FDA and Health Canada are anticipated by the end of 2025. The company is optimistic about addressing deficiencies in its applications and is preparing for a potential North American commercial launch.
DrugSorb ATR Market Opportunity: The device has an initial market opportunity of more than $300 million, with the potential to exceed $1 billion as Brilinta becomes generic and DrugSorb ATR expands to additional uses.
Core Business Financial Goals: The company aims to achieve near-term breakeven and long-term financial independence by the end of 2025, while continuing to invest in growth and operational discipline.
Sepsis Treatment Expansion: The company is focusing on expanding the use of CytoSorb in sepsis and septic shock treatment, emphasizing early, intensive, and sufficiently long treatment to improve patient outcomes.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Two regulatory agencies have now issued denials for your submissions and you continue to express confidence. Is there anything else you can give us to just kind of help us get some more confidence or kind of feel confident as you do that you're going to reach the approval goal?
A:The appeals process allowed the company to present the story of DrugSorb ATR and its impact on reducing perioperative bleeding in CABG patients. External cardiac surgery experts supported the application, and testimony was given to FDA senior officials. The company awaits a response from the FDA by the end of the month. For Health Canada, the decision is pending the conclusion of FDA discussions.
Q:Can you give us an update on Germany and how things are trending so far quarter-to-date?
A:The reorganization in Germany is a work in progress, aimed at improving the efficiency and effectiveness of the sales team. Second-quarter results showed a 22% sequential and year-over-year increase. However, more work is needed to achieve the desired operational improvements.
Q:Is the 'request for reconsideration' in Canada effectively the same as your FDA appeal?
A:The 'request for reconsideration' in Canada is similar to the FDA appeal. It involves filing an intent for reconsideration, followed by a formal appeal document, leading to a formal appeals process. The process is being delayed until after the FDA decision.
Q:Can you refresh our memory on the commercial launch rollout once approved in the U.S.?
A:The rollout will be purposeful, focusing on clinical accounts that participated in the clinical study and a few others showing interest. The first 3 to 6 months will target 22 accounts and a few additional ones to evaluate access, reorder points, and volume. The team has laid out a strategy for effective evaluation.
Q:How does the data on sepsis and septic shock translate to the business model?
A:Sepsis and septic shock are major ICU applications, accounting for 10%-20% of ICU patients and up to 15% of a hospital's operating budget. CytoSorb has been used for this application since the beginning, contributing significantly to critical care revenue. The company aims to teach users how to achieve excellent outcomes with CytoSorb, focusing on early, aggressive, and appropriately timed treatment.
Q:What can we expect for gross margins in Q3 and Q4? Can you do better than 70.9%?
A:Gross margins have been stable around 71%, with opportunities to improve through faster production ramp-up and efficiency improvements. DrugSorb approval is expected to contribute to higher margins over time.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the timeline for Health Canada's decision, stating only that it would follow the FDA's decision. Additionally, while discussing gross margins, the response lacked precise targets or timelines for achieving higher margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Corp
Day webinar
Sepsis Day
Wednesday
World Sepsis
antibiotic
appeal process
awareness month
care therapy
collapse
de novo
deficiency
fluid
increase currency
inflammation shock
leak overload
month World
mortality patient
need therapy
noncash stock
organ failure
overload organ
pathway
patient CytoSorb
people
progress reorganization
reconsideration
reduction need
registry
sale record
sepsis awareness
sepsis shock
shock patient
standard care
storm toxin
treatment sepsis
update DrugSorb
update progress
use CytoSorb
CTSO Transcript
Cytosorbents Corporation (CTSO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a 15% revenue growth and improved gross margins, which are positive indicators. However, the continued net loss and increased operating expenses temper the optimism. The lack of strategic initiatives and operational updates, along with regulatory risks, further contribute to a neutral sentiment. Without additional insights from the Q&A and specific market cap information, the stock price is likely to remain relatively stable in the short term.
Cytosorbents Corporation (CTSO) Q4 2025 Earnings Call Transcript
Unknown3-25
The earnings call presents mixed signals: improved financial metrics and gross margins are positive, but the increased operating loss and lack of specific guidance on FDA processes and German market improvements create uncertainty. The Q&A reveals cautious optimism but lacks concrete timelines and data. The absence of a new partnership or shareholder return plan further tempers any positive outlook. Therefore, the stock price is likely to remain stable in the short term.
Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance shows positive growth in revenue and gross margin, but challenges like FDA delays, cash flow issues, and market competition create uncertainties. The Q&A session revealed management's optimism about margin improvement and sepsis treatment expansion but lacked clarity on German sales restructuring. Given these factors, the stock is likely to experience a neutral movement in the short term, as positive financial indicators are offset by regulatory and operational challenges.
Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. While there's positive growth in product sales and improved operating losses, the regulatory setbacks and lack of clear guidance on gross margins are concerning. The Q&A section reveals management's confidence in overcoming regulatory hurdles, but the lack of specificity and delays may worry investors. The stable gross margins and improved financial metrics are offset by increased operating expenses and regulatory uncertainties, resulting in a neutral sentiment. The absence of market cap information limits the prediction's precision.
CTSO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
